List of Cell Therapies Companies in Utah - 6

DiscGenics is a privately held, clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine. DiscGenics is harnessing the restorative potential of cells native to the intervertebral disc to develop what we hope will be a profound therapeutic option for millions of patients suffering from the debilitating effects of back pain. DiscGenics’ first product candidate, IDCT, is a homologous, allogeneic, injectable cell therapy for the treatment of patients with mild to moderate degenerative disc disease.

Noorda-COM Pre-Accreditation Status Commission on Osteopathic College Accreditation (COCA) predoc@osteopathic.org Noorda-COM is a private institution situated at the edge of the East Bay Golf Course in Provo, Utah. Our mission at Noorda-COM is to empower our students with essential personal and professional skills needed to be competent, confident, and compassionate osteopathic physicians who are dedicated to meeting the healthcare challenges of the communities in which they serve. Our values align with instilling and fostering cultural awareness and ethical leadership, embracing diversity, and inspiring a servant's heart towards caring for the poor and needy. Noorda-COM offers osteopathic programs endorsed by local universities, Brigham Young and Utah Valley. Over the course of our program, students will expand on their medical experiences through simulation, clinical rotation, clerkship, and research projects. Our local healthcare providers are willingly partnered with us to complete this clinical portion of a medical education. Noorda-COM curriculum utilizes a blended classroom structure. No large classrooms, no regularly scheduled classes. Students will make their own schedule to meet in groups to complete modules and are assessed based on their progress. Module content is continuously being improved, since our staff is able monitor which lessons are effective with students and lessons that are not. Our campus is designed with the intention to create a stress-free environment. In addition to the incredible mountain-range view, our campus will have other attractive amenities including comfortable study areas for single person or group use, student and faculty lounges, fitness and recreation areas including access to the golf course and will be adjacent to campus housing.

Q Therapeutics is a biotechnology company based out of 417 S Wakara Way, Salt Lake City, UT, United States.

RxCell is a biotechnology company that specializes in the development of advanced cell-based therapies for the treatment of various diseases and medical conditions.

SymbioCellTech (SCT) is an early stage, university spin out, that has developed stem cell-based technology that achieves euglycemia (glucose control) in Type-1 Diabetes, and will soon be adapted for Type-2 Diabetes. The SCT proprietary Neo-Iset therapy, comprising both pancreatic islet and mesenchymal stem cells, can be administered in a simple out-patient procedure resulting in glucose control identical to that of a normal healthy individual. Backed by rigorous NIH, VA and privately funded research and resultant data, SCT has completed pre-clinical trials and is preparing for FDA submission and approval to begin well-designed, controlled, clinical trials treating humans suffering from Type-1 Diabetes. FDA Investigational New Animal Drug (INAD) approval for diabetic companion animals has been approved and canine clinical trials are ongoing with outstanding results and outcomes.

Thunder Biotech, Inc. is an immune-oncology company developing patented MOTO-CAR™ technology - genetically engineered CAR macrophages - that help cancer patients' immune cells recognize and attack solid tumors. Traditional cancer treatments— like surgery, radiation, and chemotherapy—are often ineffective, invasive, and difficult to tolerate. Thunder Biotech is designing MOTO-CAR™s to be a more effective and humane therapy. Thunder Biotech's MOTO-CAR™s re-educate Tumor Associated Macrophages and restore their M1 ability to recognize and eliminate tumor cells. In addition, MOTO-CAR™s are armed with tumor specific receptors that directly adhere to the tumor cell surface allowing them to initiate tumor cell destruction and recruit the natural T cell response engaging them to eliminate the tumor. This T cell response will then provide the body with a memory response preventing tumor recurrence.